151 related articles for article (PubMed ID: 35973227)
1. Obesity and Breast Cancer Metastasis across Genomic Subtypes.
Olsson LT; Walens A; Hamilton AM; Benefield HC; Fleming JM; Carey LA; Hursting SD; Williams KP; Troester MA
Cancer Epidemiol Biomarkers Prev; 2022 Oct; 31(10):1944-1951. PubMed ID: 35973227
[TBL] [Abstract][Full Text] [Related]
2. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
4. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
[TBL] [Abstract][Full Text] [Related]
5. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
6. Body size across the life course and risk of premenopausal and postmenopausal breast cancer in Black women, the Carolina Breast Cancer Study, 1993-2001.
Robinson WR; Tse CK; Olshan AF; Troester MA
Cancer Causes Control; 2014 Sep; 25(9):1101-17. PubMed ID: 24924530
[TBL] [Abstract][Full Text] [Related]
7. Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
Benefield HC; Allott EH; Reeder-Hayes KE; Perou CM; Carey LA; Geradts J; Sun X; Calhoun BC; Troester MA
J Natl Cancer Inst; 2020 Jul; 112(7):728-736. PubMed ID: 31742342
[TBL] [Abstract][Full Text] [Related]
8. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
9. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
[TBL] [Abstract][Full Text] [Related]
10. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Dignam JJ; Wieand K; Johnson KA; Raich P; Anderson SJ; Somkin C; Wickerham DL
Breast Cancer Res Treat; 2006 Jun; 97(3):245-54. PubMed ID: 16331345
[TBL] [Abstract][Full Text] [Related]
11. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
[TBL] [Abstract][Full Text] [Related]
12. Body mass index, waist-to-hip ratio and late outcomes: a report from the Shanghai Breast Cancer Survival Study.
Zhang M; Cai H; Bao P; Xu W; Qin G; Shu XO; Zheng Y
Sci Rep; 2017 Aug; 7(1):6996. PubMed ID: 28765555
[TBL] [Abstract][Full Text] [Related]
13. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study.
Parada H; Sun X; Fleming JM; Williams-DeVane CR; Kirk EL; Olsson LT; Perou CM; Olshan AF; Troester MA
Breast Cancer Res; 2017 Dec; 19(1):131. PubMed ID: 29228969
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
[TBL] [Abstract][Full Text] [Related]
15. Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer.
Patel A; García-Closas M; Olshan AF; Perou CM; Troester MA; Love MI; Bhattacharya A
Cancer Res; 2022 Jan; 82(1):25-35. PubMed ID: 34711612
[TBL] [Abstract][Full Text] [Related]
16. mTOR pathway candidate genes and obesity interaction on breast cancer risk in black women from the Women's Circle of Health Study.
Ilozumba MN; Yaghjyan L; Datta S; Zhao J; Hong CC; Lunetta KL; Zirpoli G; Bandera EV; Palmer JR; Yao S; Ambrosone CB; Cheng TD
Cancer Causes Control; 2023 May; 34(5):431-447. PubMed ID: 36790512
[TBL] [Abstract][Full Text] [Related]
17. Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.
Mohamed A; Olsson LT; Geradts J
Breast Cancer Res Treat; 2023 Oct; 201(3):447-460. PubMed ID: 37453958
[TBL] [Abstract][Full Text] [Related]
18. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
[TBL] [Abstract][Full Text] [Related]
19. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
[TBL] [Abstract][Full Text] [Related]
20. Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women?
Cui Y; Whiteman MK; Langenberg P; Sexton M; Tkaczuk KH; Flaws JA; Bush TL
J Womens Health Gend Based Med; 2002; 11(6):527-36. PubMed ID: 12225626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
